Dialysis Changes the Rules: What Happens When Patients With Diabetes Use Real-Time CGM?

Managing glucose is rarely simple for people with Type 2 diabetes who receive maintenance hemodialysis. Dialysis can change glucose patterns, insulin needs, and the reliability of familiar measures such as A1C. As a result, clinicians may have an incomplete picture when making treatment decisions. New randomized research on CGM use in people with diabetes on dialysis offers useful evidence about whether real-time continuous glucose monitoring can fill some of those gaps. The findings suggest that CGM may improve time in range and reduce hyperglycemia, although its effect on hypoglycemia was less clear.

Table of Contents

• Why hemodialysis makes glucose management difficult
• What the randomized real-time CGM trial tested
• How real-time CGM affected time in range and hyperglycemia
• What CGM findings in dialysis mean for diabetes care
• Conclusion
• Frequently Asked Questions

Why Hemodialysis Makes Glucose Management Difficult

Kidney failure changes many of the usual rules of diabetes care. For example, reduced kidney function can alter insulin clearance and increase the risk of unexpected glucose changes. Hemodialysis adds another layer because glucose levels may shift during and after individual treatment sessions.

Research using continuous glucose monitoring has found that glucose concentrations can fall during hemodialysis, with lower readings appearing toward the end of treatment. However, hyperglycemia can also occur, including significant excursions after dialysis. Therefore, a single fingerstick glucose result may miss important changes happening throughout the day.

A1C can also become harder to interpret. Anemia, shortened red blood cell survival, erythropoiesis-stimulating therapy, transfusions, and other factors associated with advanced kidney disease can influence A1C. Consequently, the number may not always reflect a patient’s true glucose exposure.

The ADA and KDIGO consensus report recognizes these limitations. The organizations support using CGM to evaluate treatment safety and effectiveness in people at risk for hypoglycemia and when A1C does not accurately represent overall glycemia.

For people managing diabetes during dialysis, that distinction matters. CGM does not simply produce another average. Instead, it reveals time in range, time above range, time below range, trends, and glucose variability throughout the day and night. This broader view may help clinicians identify patterns that conventional measurements overlook.

What the Randomized Real-Time CGM Trial Tested

A randomized clinical trial published in Diabetes Care in 2026 directly examined this question. Researchers studied adults with Type 2 diabetes and end-stage kidney failure who were receiving maintenance hemodialysis.

The prospective randomized crossover trial compared real-time CGM with capillary blood glucose testing. Because participants experienced both approaches, investigators could evaluate how glucose outcomes changed when real-time information became part of diabetes management.

The primary outcome was time below 70 mg/dL. This measure was particularly important because people with kidney failure may face an increased risk of hypoglycemia. In addition, researchers examined time in range, mean glucose, and time spent above important hyperglycemia thresholds.

Notably, the primary outcome did not significantly improve. Time below 70 mg/dL was 1.17% with real-time CGM compared with 1.29% during capillary glucose monitoring. The difference was not statistically significant.

However, hypoglycemia was uncommon overall. Therefore, there was relatively little time below range for the intervention to reduce. The more striking CGM findings in patients receiving dialysis appeared elsewhere in the glucose profile.

Real-Time CGM Improved Time in Range and Hyperglycemia

During real-time CGM use, participants spent 63.4% of their time between 70 and 180 mg/dL. During capillary blood glucose monitoring, time in range was 54.5%.

That represents nearly nine additional percentage points in the target range. Meanwhile, average glucose decreased from 187.7 mg/dL with capillary testing to 173.6 mg/dL during the real-time CGM intervention.

Hyperglycemia also improved. Time above 180 mg/dL declined from 44.3% with capillary monitoring to 35.3% with real-time CGM. Moreover, time above 250 mg/dL decreased from 18.8% to 12.3%. These differences were statistically significant.

The published Diabetes Care trial therefore suggests that the main benefit was not prevention of hypoglycemia in this particular group. Instead, real-time CGM helped participants spend more time in the recommended glucose range while reducing exposure to high glucose levels.

That distinction is clinically useful. Fingerstick testing offers individual snapshots, whereas CGM shows direction and duration. Consequently, patients and clinicians can see patterns that might otherwise remain hidden between measurements. For someone undergoing regular hemodialysis, those patterns may provide valuable context when evaluating glucose management.

What CGM Findings in Dialysis Mean for Diabetes Care

The trial strengthens the case for considering CGM as a management tool in this difficult population. However, the findings should not be interpreted as proof that every dialysis patient with diabetes needs continuous monitoring.

First, the study focused on glucose outcomes rather than long-term complications, cardiovascular events, hospitalization, or mortality. Future studies will need to determine whether improvements in time in range translate into better clinical outcomes.

Second, CGM use in dialysis still has practical limitations. A consensus report on CGM in chronic kidney disease discusses important considerations surrounding continuous glucose monitoring in people with advanced kidney disease. Access, insurance coverage, patient education, and device-specific considerations may also affect real-world use.

Still, continuous monitoring addresses an important weakness of conventional assessment. A1C can become less reliable as kidney disease advances, while occasional fingerstick measurements can overlook significant swings in glucose.

Real-time alerts and trend arrows may also help patients recognize where glucose is heading instead of simply showing where it was at one moment. In a population dealing with complex medication schedules, dialysis sessions, dietary restrictions, and changing insulin requirements, that extra context could be valuable.

Clinicians should still individualize treatment and consider symptoms, medications, dialysis schedules, nutrition, and confirmatory glucose testing when readings do not match the clinical picture. Patients who need individualized medical guidance should speak with their healthcare team or consult a qualified professional through Healthcare.pro.

Conclusion

The latest randomized evidence strengthens the case for CGM in people with diabetes receiving dialysis. Real-time CGM did not significantly reduce time below 70 mg/dL in adults with Type 2 diabetes receiving maintenance hemodialysis. However, participants already spent relatively little time in hypoglycemia.

The benefits appeared primarily in overall glucose management. Real-time CGM increased time in range from 54.5% to 63.4%, reduced mean glucose, and lowered time spent above both 180 and 250 mg/dL.

Therefore, continuous monitoring may offer clinicians and patients information that A1C and intermittent fingersticks cannot provide. Larger and longer trials are still needed, especially to determine whether these improvements translate into better health outcomes. For now, the evidence suggests that real-time CGM can be a clinically useful tool for selected patients facing the combined challenges of diabetes and hemodialysis.

Frequently Asked Questions

Does dialysis affect blood glucose levels?

Yes. Hemodialysis can contribute to changing glucose patterns during and after treatment. Kidney failure also affects insulin metabolism and other processes involved in glucose regulation.

Is A1C reliable for people receiving dialysis?

A1C has important limitations in advanced kidney disease. Anemia, shortened red blood cell survival, transfusions, and erythropoiesis-stimulating treatments can affect results. Clinicians may therefore use glucose monitoring alongside A1C to obtain a broader picture.

Did real-time CGM reduce hypoglycemia in the randomized trial?

No significant reduction was found. Time below 70 mg/dL was 1.17% during real-time CGM compared with 1.29% during capillary glucose monitoring. However, time below range was already low.

Did CGM improve time in range for patients receiving hemodialysis?

Yes. In the trial, time in the 70 to 180 mg/dL range increased from 54.5% with capillary glucose monitoring to 63.4% during the real-time CGM intervention. Measures of hyperglycemia also improved.

Should every person with diabetes on dialysis use CGM?

Not necessarily. Diabetes treatment should be individualized, and more research is needed on long-term clinical outcomes. However, the randomized trial suggests that real-time CGM can provide useful information and improve several glucose metrics in adults with Type 2 diabetes receiving hemodialysis.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.